COPENHAGEN, Denmark--(BUSINESS WIRE)-- Genmab A/S (Nasdaq: GMAB) today announced that the Japan Ministry of Health, Labour and Welfare has approved TIVDAK® (tisotumab vedotin) for the treatment of ...

A 30% reduction in the risk of death versus. investigator’s choice of chemotherapy as second or third line therapy was concluded when Tivdak was combined for the treatment of recurrent or metastatic ...

Tivdak improved overall survival in patients with recurrent or metastatic cervical cancer, compared with chemotherapy alone. The treatment of Tivdak (tisotumab vedotin-tftv) for patients with ...

COPENHAGEN, Denmark--(BUSINESS WIRE)-- Genmab A/S (Nasdaq: GMAB) and Pfizer, Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has accepted the supplemental Biologics ...

Credit: Getty Images. Tivdak is a tissue factor-directed antibody and microtubule inhibitor conjugate. Tivdak ® (tisotumab vedotin-tftv) improved overall survival in patients with recurrent or ...

Results showed that treatment with Tivdak met the primary endpoint of overall survival demonstrating a 30% reduction in the risk of death compared with chemotherapy. The Food and Drug Administration ...

Two months after saying it couldn't recommend Genmab's cervical cancer therapy Tivdak for use by the NHS, reimbursement ...

“TIVDAK is the only U.S. Food and Drug Administration-approved therapy in second-line recurrent or metastatic cervical cancer regardless of biomarker status, tumor histology and prior therapy,” said ...

As the Federal Trade Commission (FTC) scrutinizes Pfizer’s $43 billion Seagen buyout, the antibody-drug conjugate (ADC) specialist has notched a phase 3 win that could broaden its cervical cancer ...

“The Cervical Cancer Geographical Burden Analyzer has potential to help expand understanding of cervical cancer disease burden across different communities,” said Tara Castellano, M.D., Gynecologic ...